Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023 10

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023 10

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023 10

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023 10

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023 19

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023 19

Personalised blood test could help predict which lung cancers might return

byGraeme Sneddon| News1 April 2022Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, accordi

Updated on: December 19,2023 24

Personalised blood test could help predict which lung cancers might return

byGraeme Sneddon| News1 April 2022Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, accordi

Updated on:December 19,2023 24

Chinese medicine ingredients found to generate autophagic flux to suppress tumor progression in gastric cancer

byScience China PressActivation of Beclin-1 by piceatannol promotes autophagic flux in GC cells, and combined with everolimus, triggers autophagic death, ultimately inhibiting tumor progression,

Updated on: December 21,2023 10

Chinese medicine ingredients found to generate autophagic flux to suppress tumor progression in gastric cancer

byScience China PressActivation of Beclin-1 by piceatannol promotes autophagic flux in GC cells, and combined with everolimus, triggers autophagic death, ultimately inhibiting tumor progression,

Updated on:December 21,2023 10

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023 18

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023 18

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on: October 21,2024 0

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on:October 21,2024 0

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023 10

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023 63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023 63

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on: December 19,2023 14

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on:December 19,2023 14

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Updated on: December 19,2023 8

Targeting enzyme could alleviate muscle wasting for cancer patients

byUniversity of Texas Health Science Center at HoustonCredit: Pixabay/CC0 Public DomainTargeting a specific enzyme in the muscle could help cancer patients preserve muscle mass and potentially p

Updated on:December 19,2023 8

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on: December 20,2023 23

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on:December 20,2023 23